Kiadis announces investor events for September 2020
03 Setembro 2020 - 2:00AM
Company
announces Notice of Results for the six months ended June 30,
2020
Amsterdam, The Netherlands, September 3,
2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company developing innovative cell-based
medicines for life-threatening diseases, announces its investor
events for September 2020.
Interim resultsKiadis will be issuing its
interim results for the six months ended June 30, 2020 at 7:00 CEST
/ 6:00 BST / 1:00 EDT on Wednesday, September 30, 2020.
Kiadis’ management will host a webcast and
conference call for analysts on Wednesday, September 30, 2020 at
15:00 CEST / 14:00 BST / 9:00 EDT. A copy of the announcement will
be made available on the Kiadis website and details of the webcast
and conference call will be made available within the For Investors
section of the Company website. The webcast will be recorded, and a
replay will be made available.
In addition, members of the Kiadis management
team will participate in the following investor events in
September:
Oppenheimer Fall Healthcare Life
Sciences & MedTech SummitSeptember 21 – 23, 2020
Virtual FormatKiadis will be presenting on Monday, September 21,
2020 at 11:40 EDT and participating in one-on-one meetings with
investors on September 21.
KBC Virtual Life Sciences
ConferenceSeptember 22 – 23, 2020Kiadis will be presenting
on Tuesday, September 22, 2020 at 9:00 CET and participating in
one-on-one meetings with investors on September 22 and 23.
Kiadis contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring LifeSciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
Dutch Translation/Nederlandse
vertaling
Kiadis nv ('Kiadis') is een
Nederlands beursgenoteerd biotechbedrijf dat nieuwe geneesmiddelen
ontwikkelt tegen ernstige ziekten, maakt de financiële kalender
voor de maand september bekend.
Halfjaarresultaten
Kiadis zal haar resultaten over de eerste zes
maanden van 2020 publiceren op 30 september aanstaande om 07:00 uur
in de ochtend.
In de middag houdt Kiadis’ management om 15:00
uur een conference call voor analisten. De call vindt plaats in het
Engels. De aankondiging wordt gepubliceerd op de website van
Kiadis. De details voor toegang tot de call/webcast zijn te vinden
onder For Investors. Een opname van de webcast zal kort na afloop
beschikbaar zijn.
Financiële conferenties
Leden van het management van Kiadis nemen in
september daarnaast deel aan een aantal financiële
conferenties:
Oppenheimer Fall Healthcare Life
Sciences & MedTech Summit
Van 21 – 23 september 2020, Virtueel online
Kiadis presenteert op maandag 21 september 2020
om 11:40 EDT (05:40 Europese tijd) en neemt op 21 september deel
aan een-op-een-bijeenkomsten met investeerders.
KBC Virtual Life Sciences
Conference
Van 22 – 23 september 2020
Kiadis presenteert op dinsdag 22 september 2020
om 9.00 uur Europese tijd en neemt deel aan
een-op-een-bijeenkomsten met investeerders op 22 en 23
september.
Dit persbericht vormt een vertaling van
het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis
Founded in 1997, Kiadis is building a fully
integrated biopharmaceutical company committed to developing
innovative cell-based medicines for patients with life-threatening
diseases. With headquarters in Amsterdam, the Netherlands, and
activities across the United States, Kiadis is reimagining medicine
by leveraging the natural strengths of humanity and our collective
immune system to source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis’ or, as
appropriate, Kiadis’ officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis expressly disclaims any obligation or
undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.